SCHEMBL25614588

SCHEMBL25614588

C#Cc1cncc(-n2cccn2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 3/20 0.44
CHRNB4 P30926 5/20 0.40
CHRNA3 P32297 5/20 0.40
CHRNB2 P17787 4/20 0.40
CHRNA4 P43681 4/20 0.40
NOTUM Q6P988 1/20 0.40
LMNA P02545 2/20 0.37
MAPT P10636 2/20 0.37
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
G6PD P11413 1/20 0.37
KMT2A Q03164 1/20 0.37
MAPK1 P28482 1/20 0.37
CYP2A6 P11509 1/20 0.34
GRM5 P41594 3/20 0.34
CHRNA1 P02708 3/20 0.33
CHRNG P07510 1/20 0.33
CHRNB1 P11230 1/20 0.33
CHRND Q07001 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30811674 1.00 KDM4E (0.44) KDM4EALDH1A1CHRNB4CHRNA3CHRNB2
SCHEMBL25614598 0.78 KDM4E (0.40) KDM4EALDH1A1NOTUMLMNAMAPT
SCHEMBL27822298 0.78 NOTUM (0.44) KDM4EALDH1A1NOTUMLMNAMAPT
SCHEMBL25619586 0.77 NOTUM (0.42) CHRNB4CHRNA3CHRNB2CHRNA4NOTUM
SCHEMBL19995035 0.75 NOTUM (0.58) KDM4EALDH1A1NOTUMLMNAMAPT
SCHEMBL25614467 0.75 CHRNA3 (0.44) CHRNB4CHRNA3CHRNB2CHRNA4CYP2A6
SCHEMBL25614130 0.75 CHRNB2 (0.48) CHRNB4CHRNA3CHRNB2CHRNA4MAPT
SCHEMBL25614364 0.75 CYP2A6 (0.46) KDM4EALDH1A1CHRNB4CHRNA3CHRNB2
SCHEMBL3346335 0.74 KDM4E (0.48) KDM4EALDH1A1NOTUMLMNAMAPT
SCHEMBL10153195 0.74 KDM4E (0.48) KDM4EALDH1A1CHRNB4CHRNA3CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4582422-A1 METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Global Health Drug Discovery Institute (CN) 2025-07-09 EP disclosed
US-20250214997-A1 METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF GLOBAL HEALTH DRUG DISCOVERY INSTITUTE (CN) 2025-07-03 US disclosed
WO-2024056099-A1 METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 北京华益健康药物研究中心 2024-03-21 WO disclosed
WO-2023104209-A1 METTL3 INHIBITOR COMPOUND 上海昂阔医药有限公司 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214997-A1 METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF METTL3, METTL14, METTL16 KDM4E 172/4885ALDH1A1 893/4885CHRNB4 4350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.